October 12, 2017
Leading researcher Dr. Deborah Donnell tells us why the HIV Prevention Trials Network (HPTN) changed the design of one of two trials testing long-acting cabotegravir, as an injectable PrEP. Deb Donnell is an expert statistician, one of the great minds behind trial design and one of the best teachers we know.
Listen to the full podcast (11:56).
Highlights
- Key terms: Placebo-controlled, blinded, non-inferiority, superiority, double-dummy double-blind & open-label (2:18)
- Initial trial design for 083 vs 084: Why they started out so different (4:33)
- Finalized trial design for 083 & 084: The gold standard (1:57)
- The future of vaccine development and prevention research in the era of PrEP (1:38)
Additional Resources
- AVAC's Px Wire, Vol. 10, No. 2
- HPTN 083
- HPTN 084
- AVAC's Introduction to Long-Acting Injectables Infographic
Give this podcast a listen and tell us what you think!
More Px Pulse
For more episodes of Px Pulse, click here.